Since the early days of plasmafractionation, plasma and derivatives have been identified as being responsible for a spectrum of mild to life-threatening reactions, but it is increasingly being recognised that plasma and its derivatives may be responsible for a wider range of reactions in recipients and more frequently than is commonly appreciated by clinicians. These reactions may be related to immunological differences between the donor and the recipient, either with the component being antigenic to the recipient or the plasma containing an antibody reacting with a recipient antigen. Secondly, there may be physicochemical characteristics of the plasma component such as temperature, additives, alterations due to preparative process and accumulation of metabolites or cellular release products on storage. All of these may in some patients be responsible for clinically significant reactions. This review presents a broad overview of the clinical presentations of recipient reactions due to plasma or plasma components and their underlying mechanisms. Unless there is an immediate or acute fulminant reaction to the infusion of plasma component, adverse effects of these blood products frequently go unrecognised and untreated. Some of the reactions, if undiagnosed, may have a significant effect on the outcome of the patient. There are also various preventative measures which may be taken in the preparation of blood products or their administration to minimise their potential adverse effects.
CLINICAL MANIFESTATIONS
There is a wide spectrum of clinical manifestations of reaction to plasma and plasma components, usually depending on the mechanism of the reaction. I Clinical syndromes include: allergic and immediate generalised reactions (IGR), hypotension, intravascular or extravascular haemolysis, acute respiratory distress syndrome (ARDS), transfusion-related infection, abnormal or spurious serological results (transfusion and microbiology laboratories).
Allergic and Immediate Generalised Reactions
There has been considerable debate over the years as to the classification of allergic reactions to blood components and blood substitutes. Much of this confusion stems from our ignorance of the basic underlying pathophysiology and mediators involved. Clinical severity may range from minor urticarial reactions or flushing through to fulminant cardiorespiratory collapse and death. Many of these reactions are probably true anaphylaxis, but in others, mechanisms have been less clear and the term anaphylactoid has been used. Currently to avoid implying the mechanism of the reaction, the term immediate generalised reaction (lGR) (Figure 1) is preferred. 2 The c1incal syndromes of immediate reactions have been classified as follows:
Grade I Skin manifestations
Grade 11
Mild to moderate hypotension Gastrointestinal disturbances (nausea) Respiratory distress
Grade III

Severe hypotension, shock Bronchospasm
Grade IV Cardiac and/or respiratory arrest
PATHOPHYSIOLOGICAL MECHANISMS
There are a wide range of pathophysiological mechanisms by which plasma and plasma components may cause adverse effects in a recipient ( Figure 2 ).
Immunological Differences
The normal components of plasma may be immunologically different from the recipient in two ways. 1. Plasma proteins may contain epitopes on their molecules different from those on the recipient's functionally identical plasma proteins. 2. There may be antibodies in the donor plasma which react with cellular components of the recipient's blood cells or plasma proteins.
Immune reactions against donor plasma protein antigens
Recipients who are immunised against foreign plasma protein antigens may suffer immediate hypersensitivity reactions ranging from pruritis and urticaria at one end of the spectrum through to fulminant immediate generalised reactions (lGR) which may be fatal. On the other hand, there may be no specific allergic reactions to the blood product, but the product may be destroyed and functionally inactive (e.g. Factor VIII antibodies).
Class-specific anti-lgA antibodies in selective IgA deficiency
Patients with selective IgA deficiency (i.e. serum IgA < 0.05g/1 and normal IgG and IgM levels) are at particular risk of acute allergic reactions to any blood product containing IgA ( Figure 3 ).1." In such cases it is possible to demonstrate IgG anti-IgA alloantibodies. The clinical features of the reaction are due to activation of the complement system with release of anaphylotoxins with kinin-and histamine-releasing potential. The classical severe clinical picture is manifested within seconds of transfusion, the patient complaining of apprehension, pain (chest, lumbosacral or abdominal), dyspnoea, nausea and chills progressing to circulatory collapse and unccnsciousness. This is an important syndrome to recognise, otherwise the reaction may be repeated. Unfortunately, when all the results exclude a red cell serological incompatibility, the sequence of events is frequently "re-enacted" with a repeat of the anaphylactic reaction. The risk of an IGR is generally confined to subjects with deficiency of all IgA class antibodies and a high titre (> 256) of class-specific anti-IgA antibodies. The reported incidence of selective IgA deficiency varies from one in 442 to onc in 2000 of the population and 
SUbclass-specijic and limited specijicity anti-IgA antibodies
These anti-IgA antibodies are of limited specificity against subclasses of IgA and occur in low titre in subjects who usually have a normal serum IgA level. A high incidence has particularly been noted following pregnancy. They are associated with milder clinical reactions, usually cutaneous in nature, but severe reactions have been recorded.
Anti-IgG antibodies
There have been rare instances where reactions against the Gm antigens have been responsible for allergic reactions but in general anti-IgG antibodies do not appear to be generally associated with clinically significant reactions.
Reactions to exogenous donor antigens
Some allergic reactions of an IgE reaginic nature have been attributed to exogenous antigens (e.g. dietary, drugs) to which the recipient was highly allergic and which were present in minute amounts in donor blood. In most cases, reactions involving this mechanism can only be assumed to have occurred, unless a meticulous and time-consuming detective approach to investigation is undertaken. l
Serum sickness
Serum sickness following transfusion classically complicates heterologous transfusion of animal plasma components, but may rarely occur after homologous blood transfusion. The symptoms begin between one and five days following transfusion and symptoms consist of rash, malaise, fever, myalgia, arthritis, tenosynovitis, pericarditis and pericardial effusions.
Reactions to high titre alloantibodies in donor plasma
Any alloantibody in high titre in donor plasma has the potential to cause a wide range of clinical reactions in the recipient (Figure 4 ). 
ABO incompatibility of donor plasma
The use of ABO incompatible plasma or plasma components is usually tolerated if only small volumes are transfused and there are not high titre anti-A or anti-B haemolysins present in the plasma. Serious haemolytic reactions may occur if there is a high titre anti-A or anti-B haemolysin present in the plasma or if large volumes of normal plasma are infused into an ABO incompatible recipient.
High titre atypical red cell alloantibody in donor plasma
It is unusual for donor plasma to contain a high titre of an atypical red cell antibody. An atypical red cell antibody refers to alloantibodies to foreign red cell antigens which are not found in a nonimmunised individual. When present they have usually been stimulated by pregnancy or previous blood transfusion. These atypical antibodies are most commonly a problem when they are identified during red cell compatibility testing. In the context of donor plasma reactions the atypical antibody needs to be in high titre to cause a clinically significant reaction. This is most commonly seen with the Rhesus and the Kell blood group systems. The red cells haemolysed are usually those of the recipient, but rare cases have occurred where there may be interdonor incompatibility with the recipient being the "vessel" in which the haemolytic reaction occurs.
The main way of avoiding haemolytic transfusion reactions due to the presence of alloantibodies in the infused plasma is to:
1. screen all plasma for high titre anti-A or anti-B haemolysins, 2. refrain from using ABO incompatible plasma unless unavoidable, 3 . screen donor plasma for high titre atypical alloantibodies, 4. ensure that ABO compatible plasma is used in procedures where large volumes of plasma are likely to be infused (e.g. massive transfusion, plasma exchange).
Delayed reactions to donor reaginic (lgE) antibodies
Occasional cases have been reported of patients becoming allergic to drugs (e.g. penicillin) or other foreign antigens (animal or foodstuffs) following transfusion. 5 Reactions of this nature are essentially of anecdotal interest. Patients may have an unexpected immediate-type allergic reaction some days following plasma transfusion. In the reported cases the reactions have been to antigens which have never caused trouble for the recipient in the past and the allergy does not persist. On detailed assessment of these cases, it has been identified that the donor was allergic to these substances and the allergy has been transiently passively transferred to the recipient. The best way to avoid such reactions is to screen out donors who have strong history of allergy. The presumed mechanism in such reactions, and in some cases proven, has been the passive transfer of IgE reaginic antibodies at the time of transfusion.
High Titre Leucoagglutinins: Transfusion associated lung injury (TRALI)
In recent years it has been increasingly recognised that the acute adult respiratory distress syndrome may be initiated by the infusion of plasma containing a high titre of leucoagglutinins. 7 " The syndrome usually has onset within one to two hours of the infusion of plasma. To prove high titre leucoagglutinins to be the cause, leucoagglutinins should be demonstrated in the donor plasma. The plasma has usually been obtained from multiparous females as these are the ones whose plasma are likely to contain high titre leucoagglutinins. This syndrome has been most frequently observed post cardiopulmonary bypass as fresh frozen plasma is commonly used in this context. As this can be an acute and fulminant syndrome, the use of extracorporeal membrane oxygenation may have a role in tiding the patient over the life-threatening event. 9
Reactions due to contaminants in donor plasma or plasma component
Donor plasma may contain various unwanted contaminants which either have their origin from the donor or result from component preparation/storage techniques. In the former category problems from infective agents and medications are usually minimised by the donor screening procedures. The preparation technique and storage conditions of blood and blood products may have a significant effect on the incidence of recipient reactions following transfusion. This is a relatively unexplored area in which there has been increasing interest in recent years. Included in this category are the following:
Plasma "activation"
It is well known that the physical handling of plasma and its freezing may lead to activation of some of the proteolytic systems. 10 Of particular importance in this respect are the complement and the kinin/kininogen systems. If these systems are activated, there may be generation of vasoactive substances and anaphylotoxins which may be responsible for reactions in the recipient. Some apparently allergic reactions to blood products may be due to vasoactive substances in the infusion. The cooling and freezing or lyophilising of plasma is known to have effects on the contact system, resulting in varying degrees of activation and release of products of the kinin system. Some plasma protein fractions have been reported as consistently producing a transient fall in blood pressure. Hypotension occurring during rapid transfusion of such a substance in a hypovolaemic patient may be misinterpreted as due to further blood loss, and with further transfusion the patient's circulation may quickly become overloaded.
Histamine generation
Recent studies have demonstrated that histamine levels increase in stored blood components and that histamine levels may be correlated with nonfebrile, nonhaemolytic transfusion reactions in the recipient. Histamine release may be stimulated in the patient by plasma components, synthetic colloids and various medications.
Generation of cytokines
With the unfolding knowledge of cytokines and their important role in cell communication, it is not surprising that studies are now being initiated to examine cytokine levels in various stored blood products. IL8 is of particular interest in this respect and high levels have been demonstrated in the supernates of stored platelet concentrates. 14 Although not included in this review, biological response modifiers, growth factors and cytokines are becoming increasingly important in therapeutics and the use of these agents is associated with significant adverse effects. 1;'16
Chemical additives
There are various chemical additives (ethylene oxide, formaldehyde, drugs) which may be responsible for immunological or non-immunological recipient reactions. Various preservatives, sterilising agents and plasticisers have been incriminated in this respect. 17·19
Physicochemical Characteristics
There are various physicochemical characteristics of plasma and plasma products which need to be considered when analysing the risk-benefit equation for the recipient.
Obviously additives such as anticoagulants (citrate and sodium ion) and various preservatives need to be considered when large volumes are infused in massive transfusion and plasma exchange settings. Although it may seem obvious, it is frequently forgotten that large infusions of colloids are associated with significant risk to the recipient. Intravenous fluids are high on the list of the iatrogenic causes of in-hospital mortality and morbidity. The body's homeostatic mechanisms have only limited capacity to deal with large volumes of infused colloid. If large volumes of plasma or plasma protein solutions are to be infused, the following factors need to be taken into consideration: cardiovascular status, blood volume, capillary permeability, venous capacitance and renal function. If excessive volumes of salt and water (crystalloid) are infused in a person with normal renal function, compensatory mechanisms will usually protect the patient from major intravascular fluid overload. However, there are no such mechanisms for handling large amounts of colloid such as plasma protein solutions and albumin which are not filtered by the kidney. The patient is dependent on his or her ability to dilate the venous capacitance vessels to avoid hypervolaemia and pulmonary congestion. It should also be remembered that if a patient does manage to compensate excessive colloid infusion, haemodilution will occur, and the anaemia may be misinterpreted as a decrease in red cell mass (e.g. due to bleeding). This incorrect interpretation may result in red cell transfusion and further hypervolaemia and the possibility of pulmonary oedema.
Hypothermia a significant and frequently underrecognised problem when large volumes of blood components and fluid are being infused into patients. This is particularly so in the massive transfusion, intensive care and plasma exchange settings. It is most important that all blood products are warmed appropriately. The temperature of blood is of little clinical importance when infused slowly over several hours. However, in the massive resuscitation setting, the rapid infusion of cold blood components can have serious and devastating effects for the recipient. Although methods have been available for some years for the warming of stored blood, the subject does not receive as much attention as it should. Technology is now available which facilitates rapid infusion of enormous volumes of blood components for resuscitation. The temperature of the blood component, the volume and rate of infusion are important parameters when considering whether hypothermia is likely to be a clinical problem. The time it takes for heat exchange to occur between the various body compartments is also important. It can be calculated that relatively small volumes of rapidly infused cold fluids can have marked effects on the temperature of the intravascular volume before they affect the total body temperature.
Hypothermia and acidosis have detrimental effects on haemostasis in the setting of massive transfusion. Hypothermia is known to cause microvascular changes that alter blood clotting and platelet function, and most data would suggest that interactions between the platelet and the vessel wall are the likely cause of the coagulopathy in hypothermia rather than alterations in the coagulation cascade. The cause of hypothermia in patients requiring massive transfusion is multifactorial including exposure, tissue hypoperfusion and inadequately warmed fluids. Not only should hypothermia be avoided, but rewarming techniques should be applied. There is considerable debate about the methods for rewarming. 20 Ferrara et al found that severe hypothermia (temperature < 34°C) occurred in 80070 of nonsurvivors and in 36070 of survivors of massive blood transfusion. 21 Of the nonsurvivors. 85070 died with or as a consequence of uncontrollable bleeding. The main cause of haemostatic failure in these patients did not appear to be related to identifiable coagulation factor deficiencies or thrombocytopenia. There was no difference in the platelet count between the survivors and the nonsurvivors. These authors also found that acidosis significantly correlated with the occurrence of haemostatic failure and increased mortality. They were unable to determine whether the acidosis was related to hypothermia or hypoperfusion. The occurrence of acidosis and hypothermia with coagulopathy has the highest mortality (90070). With the onset of coagulopathy, transfusion of blood components is relatively ineffective for correction of microvascular bleeding.
Factors which may determine the incidence and severity of noncellular transfusion reactions
Level of consciousness and cardiovascular status
Reactions to plasma products and blood volume expanders are more common in fully conscious normovolaemic or moderately volume depleted patients. Conscious patients report subjective sensations which are missed in unconscious patients; indeed almost all patients who undergo anaphylaxis or immediate generalised reactions have a particular individualised aura or set of subjective feelings.
Batch variation Atopic and allergic disease
Atopic patients are more susceptible to the effects of histamine and may release more histamine in response to a given stimulus. The incidence of reactions is higher in such patients.
Medication
Beta-blockers, antihistamines, corticosteroids, ACE inhibitors and vasodilators may interfere with response to stimulus and ability to compensate.
Rate of infusion, volume and temperature of blood component Patient factors
Pre-existing immunisation and repeated exposure to plasma and plasma components appears to increase the reaction rate. This particularly applies to patients undergoing repeated therapeutic plasma exchange or cryoprecipitate administration in haemophilia. Levels of natural inhibitors (carboxypeptidases, histaminases, complement inhibitors, serpins) may determine the ability of the patient to control the clinical effects of the release or activation of mediators.
INDIVIDUAL BLOOD COMPONENTS
Fresh Frozen Plasma
As well as the immunological reaction outlined above, problems particularly associated with fresh frozen plasma are volume, citrate, temperature, sodium content. 22 
Intravenous Immunoglobulin
In the early days, intravenous immunoglobulin therapy was associated with potentially fatal reactions relatively commonly which led to them not being used. These problems were mainly related to alterations in the immunoglobulin molecules during preparation resulting in the formation of aggregates with anticomplementary activity. These preparations of intravenous globulin produced severe vasomotor reactions including chills, flushing, generalised aches and pains, chest tightness, nausea and wheezing. More recent methods have substantially reduced the problem of immunoglobulin aggregate formation and reactions to currently available immunoglobulin preparations are relatively uncommon. Current intravenous globulin preparations are manufactured using stabilising agents and infusion of the products is carried out over several hours.
Potential clinical problems which may be associated with intravenous gammaglobulin preparations include: • Immunoglobulin aggregates. • Vasoactivity reactions. • Allergic reactions, (IGR); especially in hypogammaglobulinaemic patients and patients with selective IgA deficiency as discussed above. 23 
Plasma Protein Solutions (SPPS) and Albumin
Hypervolaemia and haemodilution due to excess infusion of this colloid is a common and frequently missed iatrogenic adverse effect of plasma protein solutions. This blood component should be used cautiously in patients with cardiorespiratory or renal compromise.
During the 1970s there were several reports of plasma protein solutions causing hypotension. In 1976 the clinical features of reactions to the rapid infusion of plasma protein solution were documented in patients undergoing plasma exchange: 27 these included flushing, /ll1aeslhesiu and Inlensiv(! Care, Vol. 21, No, I, Fehruary, 1993 fullness in the head, nasal stuffiness, constricting chest pain, abdominal pain, back pain, apprehension and hypotension. These features are similar to those observed with bradykinin infusion. It was subsequently shown some preparations of plasma protein solution contained high levels of kinin activity which may have been responsible for these reactions in some cases. However, removal of this kinin activity did not lead to a reduction in the incidence of reactions. Subsequently, it was established that many batches of plasma protein solution contained prekallikrein activator (Hageman factor fragments) which could be responsible for endogenous activation of the kallikrein-kinin system following intravenous infusion of these solutions. 28 The varying amounts of prekallikrein activator in plasma protein fraction is probably determined by the origin and nature of the source plasma as well as the preparation technique. This prekallikrein activator contamination is now removed during manufacture and hypotensive reactions have been almost eliminated.
Concern about the hypotensive effects of the rapid infusion of plasma protein solution has been rekindled in recent years following reports of reproducible hypotension during the rapid infusion of plasma protein solution (SPPS) in patients who are also on angiotensin converting enzyme (ACE) inhibitors. An interaction between the ACE inhibitors and SPPS has been postulated on the basis that ACE is also kininase II which is responsible for the breakdown of circulating kinin. 2830 As ACE inhibitors delay the metabolism of kinins and plasma protein solution may cause the release of kinins, there appears a logical explanation. It may be that the current levels of prekallikrein activator in SPPS are tolerated by patients with normal clearance mechanism for bradykinin.
PREVENTION AND TREATMENT
Anticipation, diagnosis and rapid institution of therapy determine the outcome of severe reactions to plasma components. In addition to the usual principles of resuscitation such as stopping infusion, cardiac massage, artificial ventilation and oxygen administration and specific treatment as indicated. The kinin reactions induced by plasma protein solutions resolve rapidly following cessation of infusion amd infusion of an alternative plasma volume expander. Occasionally a vasoconstrictor may be indicated.
Angioneurotic oedema
The airway should be protected by intubation if necessary. Intramuscular adrenaline 1:10000.5 ml will stop progression of angioedema. Antihistamines should then be given as angioedema may recur.
Anaesthesia and Intensive Care, Vul. 21, No. I, February, 1993 Cardiovascular collapse Cardiovascular collapse is due to vasodilation, loss of plasma volume and possibly reduced cardiac performance, consequent upon either mediator effects or hypoxia. Vasoconstrictor drugs should be used, adrenaline being the drug of choice. In addition plasma volume must be restored with large volumes of an alternative colloid solution, up to two litres. Crystalloids are ineffective and if response to adrenaline is not dramatic it can be assumed that hypovolaemia is present and infusion commenced immediately. 32 Antihistamines are of no benefit. Steroids have no proven role in experimental or human anaphylaxis but there is anecdotal evidence to support their use. In lifethreatening situations there is a case for using highdose steroid.
CONCLUSION
There are thus a wide range of mechanisms by which cellular blood components may cause transfusion reactions. In some circumstances, the cause and mechanisms are clearly understood: in others understanding of pathophysiology is only beginning to unfold. As with any unexpected clinical event in the course of the patient's illness, one must always ask the question: could the event be therapy-related, and in particular, has the patient had any blood products? In some circumstances, the complication will be immediately and clearly temporally related to the infusion of the blood products. In others the clinical complication may be further down the track and not directly associated with previous therapy such as the giving of a blood component. Most transfusion reactions are thought of in terms of an incompatible cellular component given to the patient or the patient sustaining a transfusion-transmitted infectious disease. These two main areas of transfusion reaction aside, one is left with a plethora of diverse potential mechanisms for adverse effects of transfusion and the clinician must always be on guard to identify and minimise these risks. The purpose of this review has been to highlight many of these less well recognised syndromes, their pathophysiology and management. In many cases, there are ways of preventing reactions or at least minimising their occurrence.
